Yellow fever vaccine-associated viscerotropic disease

Military Medicine

Volumn 177, Issue 4, 2012, Pages 467-469

  Rowland, Michael ^a   Plackett, Timothy P ^b   Smith, Richard ^a  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b WOMACK ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

YELLOW FEVER VACCINE;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALE; MILITARY MEDICINE; PATHOGENICITY; REMISSION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VIROLOGY; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

ADULT; HUMANS; MALE; MILITARY MEDICINE; REMISSION, SPONTANEOUS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84860617708     PISSN: 00264075     EISSN: 1930613X     Source Type: Journal    
DOI: 10.7205/MILMED-D-11-00304     Document Type: Review

References (16)

1. Frierson JG: The yellow fever vaccine: a history. Yale J Biol Med 2010; 83: 77-85.
2. Vasconcelos PF: Yellow fever in Brazil: thoughts and hypotheses on the emergence in previously free areas. Rev Saude Publica 2010; 44: 1144-9.
3. Lindsey NP, Schroederb BA, Millerc ER, et al: Adverse event reports following yellow fever vaccination. Vaccine 2008; 26: 6077-82.
4. World Health Organization: Yellow Fever Fact Sheet Number 100 January 2011. Available at http://www.who.int/mediacentre/factsheets/fs100/en/index.html; accessed August 18, 2011.
5. Monath TP, Nichols R, Archambault WT, et al: Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blinded clinical trial. Am J Trop Med Hyg 2002; 66: 533-41.
6. Staples JE, Gershman M, Fischer M: Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59: 1-27.
7. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K: Persistence of neutralizing antibodies 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981; 59: 895-900.
8. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE: 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 2007; 25: 2758-65.
9. World Health Organization: Country list: Yellow fever vaccination requirements and recommendations; and malaria situations. International Travel and Health: situation as on January 1, 2010. Geneva, Switzerland, WHO Press, 2010.
10. Camacho LA, de Aguiar SG, Freire Mda S, et al: Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica 2005; 39: 413-20.
11. Cetron MS, Marfin AA, Julian KG, et al: Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002; 51: 1-11.
12. Kitchener S: Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004; 22: 2103-5.
13. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T: Active and passive surveillance of yellow fever vaccine 17D or 17DDassociated serious adverse events: systematic review. Vaccine 2011; 29: 4544-55.
14. Belsher JL, Gaya P, Brinton M, et al: Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007; 25: 8480-5.
15. Whittembury A, Ramirez G, Hernandez H, et al: Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009; 27: 5974-81.
16. Bae HG, Domingo C, Tenorio A, et al: Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008; 197: 1577-84.